Emtricitabin, Tenofovir-alafenamid a Biktegravir
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1384/2022-SML | 19. 08. 2022 | Gilead Sciences s.r.o. | 22 637 105,92 | 20 579 187,20 | 22 637 105,92 | 20 579 187,20 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Emtricitabin, Tenofovir-alafenamid a Biktegravir_EP.pdf | Písemná zpráva zadavatele | 06. 09. 2022 06:14 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 22 637 105,92 | 20 579 187,20 | CZK |
Price Actually Paid in Each Year of Performance
| 1384/2022-SML | 2023 | 18 746 353,28 | 17 042 139,35 |
| 1384/2022-SML | 2022 | 3 890 752,64 | 3 537 047,85 |